HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reinscheid, R. K. Articles by Civelli, O. Search for Related Content PubMed PubMed Citation Articles by Reinscheid, R. K. Articles by Civelli, O. Social Bookmarking                      What's this?

Vol. 273, Issue 3, 1490-1495, January 16, 1998

Structures That Delineate Orphanin FQ and Dynorphin A Pharmacological Selectivities

From the F. Hoffmann-La Roche AG, CNS Research, Pharma Division, CH-4070 Basel, Switzerland and the ^§ Department of Pharmacology, College of Medicine, University of California, Irvine, California 92697

Strict pharmacological selectivity in families of structurally related ligands and receptors may result from a key process in evolution aiming at increasing diversity in neurotransmission. An intriguing example of such exclusive specificity can be found in the newly discovered orphanin FQ (OFQ) system when it is compared with the opioid system. Both OFQ and its receptor share a high degree of sequence similarity to the opioid peptides and their corresponding receptors, respectively. However, OFQ does not activate opioid receptors, nor do the opioid peptides elicit biological activity at the OFQ receptor. We have therefore investigated the basis for the inherent selectivity of the primary structures of OFQ and dynorphin A, its closest counterpart. A series of truncated and/or chimeric peptides led to the conclusion that both peptides contain domains which establish their pharmacological selectivity. In the OFQ molecule we could delineate a domain that prevents its ability to activate the -opioid receptor by apparently repelling its binding. In both peptides the selectivity-generating domains are composed of single residues in key positions together with short stretches of amino acids which do not overlap. To prove this concept, we designed a universal agonist and found it active at both the OFQ receptor and the -opioid receptor. Our observations suggest that a coordinated mechanism of evolution has separated the orphanin FQ system from the opioid system.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C S. Bradford, E. A Walthers, B. T Searcy, and F. L Moore Cloning, heterologous expression and pharmacological characterization of a kappa opioid receptor from the brain of the rough-skinned newt, Taricha granulosa J. Mol. Endocrinol., June 1, 2005; 34(3): 809 - 823. [Abstract] [Full Text] [PDF]

				C. M. Bullock, J.-D. Li, and Q.-Y. Zhou Structural Determinants Required for the Bioactivities of Prokineticins and Identification of Prokineticin Receptor Antagonists Mol. Pharmacol., March 1, 2004; 65(3): 582 - 588. [Abstract] [Full Text] [PDF]

				R. M. Silva, H. C. Grossman, M. M. Hadjimarkou, G. C. Rossi, G. W. Pasternak, and R. J. Bodnar Dynorphin A1-17-Induced Feeding: Pharmacological Characterization Using Selective Opioid Antagonists and Antisense Probes in Rats J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 513 - 518. [Abstract] [Full Text] [PDF]

				C. E. Owens and H. Akil Determinants of Ligand Selectivity at the kappa -Receptor Based on The Structure of the Orphanin FQ Receptor J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 992 - 999. [Abstract] [Full Text] [PDF]

				L. Mouledous, C. M. Topham, C. Moisand, C. Mollereau, and J.-C. Meunier Functional Inactivation of the Nociceptin Receptor by Alanine Substitution of Glutamine 286 at the C Terminus of Transmembrane Segment VI: Evidence from a Site-Directed Mutagenesis Study of the ORL1 Receptor Transmembrane-Binding Domain Mol. Pharmacol., March 1, 2000; 57(3): 495 - 502. [Abstract] [Full Text]

				C. Mollereau, L. Mouledous, S. Lapalu, G. Cambois, C. Moisand, J.-L. Butour, and J.-C. Meunier Distinct Mechanisms for Activation of the Opioid Receptor-Like 1 and kappa -Opioid Receptors by Nociceptin and Dynorphin A Mol. Pharmacol., February 1, 1999; 55(2): 324 - 331. [Abstract] [Full Text]

				L. Mouledous, C. M. Topham, H. Mazarguil, and J.-C. Meunier Direct Identification of a Peptide Binding Region in the Opioid Receptor-like 1 Receptor by Photoaffinity Labeling with [Bpa10,Tyr14]Nociceptin J. Biol. Chem., September 15, 2000; 275(38): 29268 - 29274. [Abstract] [Full Text] [PDF]

				P. B. Danielson, M. T. Hoversten, M. Fitzpatrick, C. Schreck, H. Akil, and R. M. Dores Sturgeon Orphanin, a Molecular "Fossil" That Bridges the Gap between the Opioids and Orphanin FQ/Nociceptin J. Biol. Chem., June 15, 2001; 276(25): 22114 - 22119. [Abstract] [Full Text] [PDF]